Focused On-demand Library for TGF-beta receptor type-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

TGF-beta type II receptor; Transforming growth factor-beta receptor type II

Alternative UPACC:

P37173; B4DTV5; Q15580; Q6DKT6; Q99474


The TGF-beta receptor type-2 (TGFBR2) is a pivotal transmembrane serine/threonine kinase that, in conjunction with TGFBR1, forms a receptor complex for TGF-beta cytokines TGFB1, TGFB2, and TGFB3. This complex plays a crucial role in transmitting the TGF-beta signal from the cell surface to the cytoplasm, influencing a wide range of processes such as cell cycle arrest, wound healing, and carcinogenesis. The receptor's ability to bind TGFB1, TGFB2, and TGFB3 with high affinity is central to its function in regulating the SMAD-dependent TGF-beta signaling cascade.

Therapeutic significance:

TGFBR2's involvement in diseases like Hereditary non-polyposis colorectal cancer 6, Esophageal cancer, and Loeys-Dietz syndrome 2 underscores its potential as a therapeutic target. Its role in these conditions highlights the importance of understanding TGFBR2's function in cancer susceptibility and systemic disorders, paving the way for innovative treatment strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.